Listed

ICU Medical Inc: Form 10-Q for the period ended Jun 30, 2023

Filed with the SEC on Aug 7, 2023 and accepted by EDGAR at Aug 7, 2023, 17:22 ET.

Share

Management's discussion and analysis

As filed, 44,607 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should read the following discussion and analysis of our financial condition and results of operations together with the condensed consolidated financial statements and accompanying notes in this Quarterly Report on Form 10-Q, as well as the audited consolidated financial statements and related notes thereto included in our 2022 Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current plans, expectations and beliefs involving risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the caption entitled “Forward-Looking Statements” in this section and Part I, Item 1A. “Risk Factors” in our 2022 Annual Report on Form 10-K.

When used in this report, the terms “we,” “us,” and “our” refer to ICU Medical, Inc. ("ICU") and its consolidated subsidiaries included in our condensed consolidated financial statements unless context requires otherwise.

Business Overview and Highlights

We develop, manufacture, and sell infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. Our product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products.

Products

In 2023, our primary product offerings have been classified into our new business units as listed below. We have presented our financial results in accordance with these product lines:

Consumables

Our Consumables business unit includes Infusion Therapy, Oncology, Vascular Access and Tracheostomy products.

Infusion Therapy

Our Infusion Therapy products include non-dedicated infusion sets, extension sets, needle-free connectors, and disinfection caps. Infusion sets used in hospitals and ambulatory clinics consist of flexible sterile tubing running from an IV bag or bottle containing a drug product or solution to a catheter inserted in a patient’s vein that may or may not be used with an infusion pump. Disinfection caps are used to actively disinfect access points into the infusion sets and catheters. Our primary Infusion Therapy products are:

  • Clave™ needlefree products, including the MicroClave, MicroClave Clear, and NanoClave™ brand of connectors, accessories, extension and administration sets used for the administration of IV fluids and medications and the Neutron catheter patency device, used to help maintain patency of central venous catheters;
  • Neutron™ catheter patency device, used to help maintain patency of central venous catheters;
  • Tego™ needlefree connector utilized to access catheters for hemodialysis and apheresis applications; and
  • ClearGuard™, SwabCap™ and SwabTip™ disinfection caps.

Oncology

Closed System Transfer Devices ("CSTD") and hazardous drug compounding systems are used to prepare and deliver hazardous IV medications such as those used in chemotherapy, which, if released, can have harmful effects on the healthcare worker and environment. Our primary Oncology products are:

  • ChemoLockTM CSTD, which utilizes a proprietary needlefree connection method, is used for the preparation and administration of hazardous drugs. ChemoLock is used to limit the escape of hazardous drug or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury;
  • ChemoClaveTM, an ISO Connection standard and universally compatible CSTD used for the preparation and administration of hazardous drugs. ChemoClave utilizes standard ISO luer locking connections, making it compatible with all brands of needlefree connectors and pump delivery systems. ChemoClave also is used to limit the escape of hazardous drug or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminate the risk of needlestick injury; and
  • Deltec® GRIPPER® non-coring needles for portal access.

The preparation of hazardous drugs typically takes place in a pharmacy where drugs are removed from vials and prepared for delivery to a patient. Those prepared drugs are then transferred to a nursing unit where the chemotherapy is administered via an infusion pump set to a patient. Components of the ChemoClave and ChemoLock product lines are used both in pharmacies and on the nursing floors for the preparation and administration of hazardous drugs.

Vascular Access

Our vascular access products allow clinicians to safely access the patients' bloodstream to deliver fluids and medication or to obtain blood samples. Our primary Vascular Access products are:

  • Jelco® safety and conventional peripheral IV catheters and sharps safety devices for hypodermic injection, designed to help prevent accidental needlestick injury;
  • Safe-T Wing® venipuncture and blood collection devices;
  • Port-A-Cath® implantable ports;
  • Portex® arterial blood sampling syringes;
  • PowerWand® midline catheters; and
  • Cleo® subcutaneous infusion catheters and sets.

Tracheostomy

Our tracheostomy products enable placement of a secure airway using both surgical and percutaneous insertion techniques. Our primary Tracheostomy products includes:

  • Portex BLUselect® PVC tracheostomy tubes feature an inner cannula as well as a Suctionaid option for above the cuff suctioning and vocalization capability;
  • Portex Bivona® silicone tracheostomy tubes offer the added benefits of comfort and mobility and come in a variety of configurations suited to meet the clinical needs of neonatal through adult patients; and
  • Portex BLUperc® percutaneous insertion kits allow for safe placement of the tracheostomy tube at the bedside.

Infusion Systems

We offer a wide range of infusion pumps, dedicated IV sets, software and professional services. Our primary Infusion System products are:

Large Volume Pump ("LVP") Hardware and Dedicated IV Sets:

  • Plum 360™: The Plum 360™ infusion pump is an ICU Medical MedNet™ ready large volume infusion pump with an extensive drug library and wireless capability. The pumps work with dedicated IV sets. Plum 360 was named the 2018, 2019, 2020, and 2022 Best in KLAS winner as top-performing IV smart pump and was the first medical device to be awarded UL Cybersecurity Assurance Program Certification. Also, in 2021 and 2022, the Plum 360 won the award as the top-performing Smart Pump EMR-Integrated.

Ambulatory Infusion Hardware:

  • CADD® ambulatory infusion pumps and disposables, including administration sets and medication cassette reservoirs, support a variety of IV pain management therapies across clinical care areas from hospital to outpatient treatment.

Syringe Infusion Hardware:

  • MedfusionTM syringe infusion pumps are designed for the administration of fluids and medication requiring precisely controlled infusion rates from a variety of syringe sizes in acute care settings.

IV Medication Safety Software:

  • ICU Medical MedNet™: ICU Medical MedNet is an enterprise-class medication management platform for any sized healthcare system that can help reduce medication errors, improve quality of care, streamline workflows and maximize revenue capture. ICU Medical MedNet connects our industry-leading smart pumps to a hospital’s EHR, asset tracking systems, and alarm notification platforms with the largest array of integration partners.
  • PharmGuard® Medication Safety Software for MedfusionTM 4000 syringe and CADD™ Solis pumps allows for customized drug libraries to support the standardization of protocols for medication administration throughout the facility.

Professional Services:

  • In addition to the products above, our teams of clinical, information technology, and professional services experts work with customers to develop and deliver safe and efficient infusion systems, providing customized and personalized configuration, implementation, and data analytics services to complement our infusion hardware and software.

Vital Care

Our Vital Care business unit includes IV Solutions, Critical Care, General Anesthesia and Respiratory, Temperature Management Solutions and Regional Anesthesia/Pain Management products.

IV Solutions

Our IV Solutions products include a broad portfolio of injection, irrigation, nutrition and specialty IV solutions including:

IV Therapy and Diluents:

  • Including Sodium Chloride, Dextrose, Balanced Electrolyte Solutions, Lactated Ringer's, Ringer's, Mannitol, Sodium Chloride/Dextrose and Sterile Water.

Irrigation:

  • Including Sodium Chloride Irrigation, Sterile Water Irrigation, Physiologic Solutions, Ringer's Irrigation, Acetic Acid Irrigation, Glycine Irrigation, Sorbitol-Mannitol Irrigation, Flexible Containers and Pour Bottle Options.

Hemodynamic Monitoring

Our Hemodynamic Monitoring products help clinicians get accurate real-time access to patients’ hemodynamic and cardiac status with an extensive portfolio of monitoring systems and advanced sensors & catheters. Measurements provided by our systems help clinicians determine how well the heart is pumping blood and how efficiently oxygen from the blood is being used by the tissues. Our Hemodynamic Monitoring products include:

  • Cogent™ 2-in-1 hemodynamic monitoring system;
  • CardioFlo™ hemodynamic monitoring system;
  • TDQ™ and OptiQ™ cardiac output monitoring catheters;
  • TriOxTM venous oximetry catheters;
  • Transpac™ blood pressure transducers; and
  • SafeSet™ closed blood sampling and conservation system.
  • MEDEX® LogiCal® Pressure Monitoring System and components.

General Anesthesia & Respiratory

We offer a broad range of anesthesia systems and devices and breathing circuits, ventilation, respiratory and specialty airway products that maintain patients’ airways before, during and after surgery. Our primary Anesthesia & Respiratory products are:

  • Portex® acapella® bronchial hygiene products used to mobilize pulmonary secretions to facilitate the opening of airways in patients with chronic respiratory diseases such as chronic obstructive pulmonary disease, or COPD, asthma and cystic fibrosis.

Temperature Management Solutions

Temperature Management solutions systems are used in perioperative and critical care settings to help monitor and regulate patient temperature. Our primary Temperature Management products include:

  • Level 1® rapid infusion, fluid warming, routine blood and fluid warming, irrigation fluid warming, convective patient warming and temperature probes.

Regional Anesthesia/Pain Management Trays

We offer a comprehensive range of Portex® regional anesthesia/pain management trays and components. Our primary products include:

  • Epidural Trays;
  • Spinal Trays;
  • Combined (CSE) Trays;
  • Peripheral Nerve Block Trays; and
  • Specialty Trays (Lumbar Puncture, Amniocentesis, Myelogram).

In the U.S. a substantial amount of our products are sold to group purchasing organization member hospitals. We believe that as healthcare providers continue to either consolidate or join major buying organizations, the success of our products will depend, in part, on our ability, either independently or through strategic relationships, to secure long-term contracts with large healthcare providers and major buying organizations.

Supply Constraints, Global Economic Conditions

We have experienced significant impacts to our business as a result of global economic challenges, resulting from the COVID-19 pandemic and the continuing conflict between Russia and Ukraine, such as rising inflation, especially with respect to freight costs driven by higher fuel prices, increased cost and shortages of raw materials, and supply chain disruptions which negatively impacted our gross profit margin during 2022. We expect the pressure on the supply chain to continue and freight costs remain subject to volatility in the market. The rising interest rates and foreign currency impact due to the strengthening of the U.S. dollar have also impacted our results of operations during 2022 and the first half of 2023.

Our business operations expose us to risks associated with public health crises and epidemics/pandemics, such as COVID-19. COVID 19 had caused lower hospital admissions and medical procedure volumes, and any resurgence of the pandemic or any new public health crisis could again shift healthcare priorities and cause volatility in the demand for our products, thereby adversely affecting our business operations.

While we continually monitor the ongoing and evolving impact of the above events on our operations, the overall impact remains uncertain and may not be fully reflected until future periods. The overall impact to our results of operations will depend on factors such as the duration and extent of the current global economic challenges and the resurgence of the pandemic or the emergence of a new public health crisis, none of which can be fully predicted at this time. See “Part I. Item 1A. Risk Factors” in our 2022 Annual Report on Form 10-K for a discussion of risks and uncertainties.

Consolidated Results of Operations

We present income statement data in Part I, Item 1. "Financial Statements." The following table shows, for the three and six months ended June 30, 2023 and 2022, the percentages of each income statement caption in relation to total revenue:

Three months ended June 30, 2023 2022 Six months ended June 30, 2023 2022
Total revenues 100% 100% 100% 100%
Gross profit 35% 30% 34% 30%
Selling, general and administrative expenses 27% 28% 27% 28%
Research and development expenses 4% 4% 4% 4%
Restructuring, strategic transaction and integration expenses 2% 2% 2% 4%
Change in fair value of contingent earn-out 1% (5)% —% (2)%
Total operating expenses 34% 29% 33% 34%
Income (loss) from operations 1% 1% 1% (4)%
Interest expense, net (4)% (3)% (4)% (3)%
Other (expense) income, net —% —% —% —%
Loss before income taxes (3)% (2)% (3)% (7)%
Benefit for income taxes 2% 2% 1% 3%
Net loss (1)% —% (2)% (4)%

Seasonality/Quarterly Results

There are no significant seasonal aspects to our business. We can experience fluctuations in net sales as a result of variations in the ordering patterns of our largest customers, which may be driven more by production scheduling and customer inventory levels, and less by seasonality. Our expenses often do not fluctuate in the same manner as net sales, which may cause fluctuations in operating income that are disproportionate to fluctuations in our revenue.

Non-GAAP Financial Measures

In addition to comparing changes in revenue on a U.S. GAAP basis, we also compare the changes in revenue from one period to another using constant currency. The presentation of revenues on a constant currency basis is a non-GAAP financial measure that excludes the impact of fluctuations in foreign currency exchange rates that occurred between the comparative periods. We provide constant currency information to enhance the visibility of underlying business trends, excluding the effects of changes in foreign currency translation rates. We believe this information is useful to investors to facilitate comparisons and better identify trends in our business. Our constant currency revenues reflect current period local currency revenues at prior period's average exchange rates. We consistently apply this approach to revenues for all currencies where the functional currency is not the U.S. dollar. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Consumables

The following table summarizes our total Consumables revenue (in millions):

Three months ended June 30, 2023 2022 $ Change % Change Six months ended June 30, 2023 2022 $ Change % Change
Consumables revenue (GAAP) $237.0 $241.0 $(4.0) (1.7)% $473.1 $481.2 $(8.1) (1.7)%
Impact of foreign exchange rate changes 1.9 7.7
Consumables revenue on a constant currency basis (non-GAAP) $238.9 $241.0 $(2.1) (0.9)% $480.8 $481.2 $(0.4) (0.1)%

Consumables revenue decreased for the three and six months ended June 30, 2023, as compared to the same periods in the prior year, primarily due to a decrease in our Vascular Access revenues and the impact of foreign exchange rate changes. These decreases were partially offset by an increase in Infusion Therapy and Tracheostomy revenues. Additionally, revenue for the six months ended June 30, 2023 included the impact of an additional eight billing days as compared to the same period in the prior year related to Smiths Medical which was acquired on January 6, 2022.

Infusion Systems

The following table summarizes our total Infusion Systems revenue (in millions):

Three months ended June 30, 2023 2022 $ Change % Change Six months ended June 30, 2023 2022 $ Change % Change
Infusion Systems (GAAP) $153.2 $148.6 $4.6 3.1% $314.9 $286.8 $28.1 9.8%
Impact of foreign exchange rate changes 2.7 7.9
Infusion Systems on a constant currency basis (non-GAAP) $155.9 $148.6 $7.3 4.9% $322.8 $286.8 $36.0 12.6%

Infusion Systems revenue increased for the three and six months ended June 30, 2023, as compared to the same periods in the prior year, primarily due to higher sales of our ambulatory infusion and syringe pump products. The increase in revenue for the six months ended June 30, 2023 was also due to the impact on revenue of an additional eight billing days related to Smiths Medical which was acquired January 6, 2022. These increases were partially offset by the impact of foreign exchange rate changes.

Vital Care

The following table summarizes our total Vital Care revenue (in millions):

Three months ended June 30, 2023 2022 $ Change % Change Six months ended June 30, 2023 2022 $ Change % Change
Vital Care (GAAP) $159.2 $171.4 $(12.2) (7.1)% $330.0 $336.1 $(6.1) (1.8)%
Impact of foreign exchange rate changes 1.2 5.3
Vital Care on a constant currency basis (non-GAAP) $160.4 $171.4 $(11.0) (6.4)% $335.3 $336.1 $(0.8) (0.2)%

Vital Care revenue decreased for the three and six months ended June 30, 2023, as compared to the same periods in the prior year, primarily due to lower sales of IV Solution and the impact of foreign currency exchange rate changes. These decreases were partially offset by higher sales of our temperature management products. The decrease in revenue for the six months ended June 30, 2023 was also partially offset by higher critical care revenue and the impact on revenue of an additional eight billing days related to Smiths Medical which was acquired January 6, 2022.

Gross Margins

For the three and six months ended June 30, 2023, gross margins were 35.0% and 34.4%, respectively, as compared to 29.9% and 30.5% for the three and six months ended June 30, 2022, respectively. The increases in gross margins for the three and six months ended June 30, 2023, as compared to the same periods in the prior year, was primarily driven by the cost recognition of the purchase accounting write-up of inventory in 2022 and lower freight costs for the three and six months ended June 30, 2023 as compared to the same periods in the prior year. These benefits were partially offset by the impact of foreign exchange rate changes.

Selling, General and Administrative (“SG&A”) Expenses

The following table summarizes our total SG&A Expenses (in millions):

Three months ended June 30, 2023 2022 $ Change % Change Six months ended June 30, 2023 2022 $ Change % Change
SG&A $150.9 $158.7 $(7.8) (4.9)% $303.5 $312.0 $(8.5) (2.7)%

SG&A expenses decreased for the three months ended June 30, 2023, as compared to the same period in the prior year primarily due to decreases of $6.1 million in depreciation and amortization, $2.6 million in dealer fees, and $1.9 million of IT expenses. These decreases were partially offset by an increase of $1.8 million in stock based compensation. Depreciation and amortization decreased as the fair market values of certain intangible assets acquired in regard to the 2022 Smiths Medical acquisition were adjusted down after the same period in the prior year. Dealer fees decreased due to a decrease in revenues to distributors. IT expenses decreased based on current operating needs. Stock based compensation increased due to an increase in the fair value of amounts awarded in the current year over the fair value of the awards in the prior year.

SG&A expenses decreased for the six months ended June 30, 2023, as compared to the same period in the prior year primarily due to decreases of $7.3 million in dealer fees and $4.6 million in depreciation and amortization. Partially offsetting these decreases were increases of $2.0 million in compensation expenses and $2.0 million in commissions. Compensation costs increased over the same period in the prior year primarily due to an increase in incentive compensation which was based on a larger employee population in the current year period. Commissions increased primarily due to the increase in revenues.

Research and Development (“R&D”) Expenses

The following table summarizes our total R&D Expenses (in millions):

Three months ended June 30, 2023 2022 $ Change % Change Six months ended June 30, 2023 2022 $ Change % Change
R&D $22.3 $22.6 $(0.3) (1.3)% $42.1 $46.4 $(4.3) (9.3)%

R&D expenses decreased for the three and six months ended June 30, 2023, as compared to the same periods in the prior year. R&D expenses during both periods primarily relate to headcount and employment expense in support of ongoing R&D projects.

Restructuring, Strategic Transaction and Integration Expenses

Restructuring, strategic transaction and integration expenses were $12.4 million and $23.4 million for the three and six months ended June 30, 2023, respectively, as compared to $13.5 million and $47.4 million for the three and six months ended June 30, 2022, respectively.

Restructuring charges

Restructuring charges were $1.3 million and $4.0 million for the three and six months ended June 30, 2023, respectively, as compared to $1.7 million and $4.9 million for the three and six months ended June 30, 2022, respectively, and were primarily related to severance costs for all periods. We expect to pay the majority of unpaid restructuring charges as of June 30, 2023 during the remainder of 2023 and 2024.

Strategic transaction and integration expenses

Strategic transaction and integration expenses were $11.1 million and $19.4 million for the three and six months ended June 30, 2023, respectively, as compared to $11.8 million and $42.5 million for the three and six months ended June 30, 2022, respectively. The strategic transaction and integration expenses during the three and six months ended June 30, 2023 were primarily related to consulting expenses and employee costs incurred to integrate our Smiths Medical business acquired in 2022. The strategic transaction and integration expenses for the three and six months ended June 30, 2022 were primarily related to transaction and integration expenses associated with our acquisition of Smiths Medical on January 6, 2022 which primarily included legal expenses, bank fees, and employee costs. The six months ended June 30, 2022 also included a United Kingdom stamp tax.

Change in Fair Value of Contingent Earn-out

For the three and six months ended June 30, 2023, there was a loss of $4.0 million and $3.3 million, respectively, primarily related to the change in fair value of contingent earn-out related to the Smiths Medical acquisition and the earn-out related to an agreement with one of our international distributors.

Interest Expense, net

The following table presents interest expense, net (in thousands):

Three Months Ended June 30, 2023 2022 Six Months Ended June 30, 2023 2022
Interest expense $(25,833) $(16,273) $(50,099) $(29,917)
Interest income 1,712 833 3,463 1,422
Interest expense, net $(24,121) $(15,440) $(46,636) $(28,495)

Interest expense, net for the three and six months ended June 30, 2023 and 2022 primarily includes the contractual interest incurred on borrowings under the Credit Agreement, the per annum commitment fee charged on the available amount of the revolving credit facility contained in the Credit Agreement and the amortization of debt issuance costs incurred in connection with entering into the Credit Agreement (see Note 17: Long-Term Debt in our accompanying condensed consolidated financial statements). The interest expense increased for the three and six months ended June 30, 2023, as compared to the respective prior year periods, primarily due to increases in the applicable SOFR reference rate. These increases were partially offset by the impact of the interest rate swaps (see Note 8: Derivatives and Hedging in our accompanying condensed consolidated financial statements).

Other Expense, net

The following table presents other expense, net (in thousands):

Three Months Ended June 30, 2023 2022 Six Months Ended June 30, 2023 2022
Foreign exchange losses, net $(501) $(2,739) $(339) $(2,516)
Loss on disposition of assets (229) (643) (526) (954)
Other miscellaneous (expense) income, net (772) 2,016 (906) 2,519
Other expense, net $(1,502) $(1,366) $(1,771) $(951)

Income Taxes

For the three and six months ended June 30, 2023, income taxes were accrued at an estimated effective tax rate of 57% and 46%, respectively, as compared to 56% and 36% for the three and six months ended June 30, 2022, respectively.

The effective tax rate for the three and six months ended June 30, 2023 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, section 162(m) excess compensation, foreign-derived intangible income (“FDII”) and tax credits. The effective tax rate for both the three and six months ended June 30, 2023 included a tax benefit of $6.0 million primarily related to unrecognized tax benefits released as a result of the expiration of the statute of limitations. The effective tax rate during the three and six months ended June 30, 2023 also included a tax benefit of $0.9 million and $0.2 million, respectively, related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock during the period. Additionally, the effective tax rate for the three and six months ended June 30, 2023 also included the nil tax impact of the revaluation of contingent consideration for $4.0 million and $3.3 million, respectively.

The effective tax rate for the three and six months ended June 30, 2022 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, section 162(m) excess compensation, FDII and tax credits. The effective tax rate during the three and six months ended June 30, 2022 included a discrete tax benefit of $0.0 million and $2.6 million, respectively, related to excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period. The revaluation of the contingent consideration during the three and six months ended June 30, 2022 resulted in a tax expense of $0.0 million for both periods.

Liquidity and Capital Resources

We regularly evaluate our liquidity and capital resources, including our access to external capital, to assess our ability to meet our principal cash requirements, which include working capital requirements, planned capital investments in our business, commitments, acquisition restructuring and integration expenses, investments in quality systems and quality compliance objectives, payment of interest expense, repayment of outstanding borrowings, income tax obligations and acquisition opportunities in accordance with our growth strategy.

Sources of Liquidity

Our primary sources of liquidity are cash and cash equivalents, our short-term investment portfolio, cash flows from our operations and access to borrowing arrangements.

Funds generated from operations are held in cash and cash equivalents and investment securities. During the six months ended June 30, 2023, our cash and cash equivalents and short-term investment securities increased by $15.3 million from $213.0 million at December 31, 2022 to $197.7 million at June 30, 2023. This increase was primarily due to cash generated from operations. Our short-term investment portfolio currently consists of investment-grade corporate and federal bonds and is primarily intended to facilitate capital preservation.

2022 Credit Agreement and Access to Capital

As discussed in Note 17: Long-Term Debt to our accompanying condensed consolidated financial statements, we entered into the Credit Agreement with various lenders on January 6, 2022 in connection with the closing of the Smiths Medical acquisition. The Credit Agreement provides for a five-year term loan A facility of $850.0 million (the "Term Loan A"), a seven-year term loan B facility of $850.0 million (the "Term Loan B") and a five-year revolving credit facility of $500.0 million (the "Revolving Credit Facility") (collectively, the "Senior Secured Credit Facilities"). The proceeds from the term loans were used to finance a portion of the cash consideration for the Smiths Medical acquisition. The outstanding aggregate principal amount of the term loans is $1.7 billion as of June 30, 2023, which includes the Term Loan A that will mature in January 2027 and the Term Loan B that will mature in January 2029. The proceeds of future borrowings under the Revolving Credit Facility, which expires in January 2027, may be used as a source of liquidity to support our ongoing working capital requirements and other general corporate purposes. There are no outstanding borrowings under the Revolving Credit Facility as of June 30, 2023. As part of entering into the Senior Secured Credit Facilities, we were assigned issuer and Term Loan B credit ratings. At the date of issuance of this report, our issuer and Term Loan B credit ratings assigned and outlook were as follows:

Issuer/Term Loan B Credit Ratings Outlook
Moody's Ba3/Ba3 Stable
Fitch BB/BBB- Negative
Standard & Poor's BB-/BB- Stable

The Credit Agreement contains financial covenants that pertain to the Term Loan A and the Revolving Credit Facility. Specifically, we are required to maintain a Senior Secured Leverage Ratio of no more than 4.50 to 1.00 until June 30, 2024, with stepdowns to 4.00 to 1.00 thereafter, and an Interest Coverage Ratio of no less than 3.00 to 1.00 (defined and discussed in greater detail in Note 17: Long-Term Debt to our accompanying condensed consolidated financial statements). We were in compliance with these financial covenants as of June 30, 2023.

We believe that our existing cash and cash equivalents along with cash flows expected to be generated from future operations including the cash received from our uncommitted trade accounts receivable purchase facility and the funds received and accessible under the Senior Secured Credit Facilities will provide us with sufficient liquidity to finance our cash requirements for the next twelve months. In the event that we experience downturns, cyclical fluctuations in our business that are more severe or longer than anticipated, fail to achieve anticipated revenue and expense levels, or have significant unplanned cash expenditures, we may need to obtain or seek alternative sources of capital or financing, and we can provide no assurances that the terms of such capital or financing will be available to us on favorable terms, if at all. Our ability to generate cash flows from operations, issue debt or enter into other financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for our products or in the solvency of our customers or suppliers, deterioration in our key financial ratios or credit ratings or other significantly unfavorable changes in economic conditions. See Part I. Item 1A. "Risk Factors” in our 2022 Annual Report on Form 10-K for discussion of the risks and uncertainties associated with our debt financing.

Uses of Liquidity

Capital Expenditures

At June 30, 2023, we estimate that our capital expenditures in 2023 will be in the range of $80 million to $100 million.

Contractual Obligations

Our principal commitments at June 30, 2023 include both short and long-term future obligations.

Operating Leases

We have non-cancelable operating lease agreements where we are contractually obligated for certain lease payment amounts. We assumed additional operating leases as a result of our acquisition of Smiths Medical. For more information regarding our operating lease obligations, (see Note 6: Leases to our accompanying condensed consolidated financial statements).

Long-term Debt

In January 2022, we incurred borrowings under Senior Secured Credit Facilities. The principal repayment obligations and estimated interest payments on the term loans and estimated commitment fee payments on the revolver are estimated in the table below. Interest payments on the term loans were estimated using an Adjusted Term SOFR rate and an initial applicable margin of 1.75% for Term Loan A and 2.50% for Term Loan B and the revolver commitment fees were estimated using the initial rate of 0.25%. The applicable margin rate and commitment fee rate will change from time to time in accordance with a preset pricing grid based on the leverage ratio (see Note 17: Long-Term Debt to our accompanying condensed consolidated financial statements for pricing grids related to the Senior Secured Credit Facilities). We expect to fund these obligations with our existing cash and cash equivalents and cash generated from our future operations.

(in millions)

Remainder of 2023 2024 2025 2026 2027 2028 Thereafter
Term Loan A Principal Payments $10.6 $42.5 $42.5 $63.8 $664.1 $— $—
Term Loan A Interest Payments 31.2 54.4 42.4 37.5 0.6 — —
Term Loan B Principal Payments 4.3 8.5 8.5 8.5 8.5 8.5 792.6
Term Loan B Interest Payments 33.9 60.9 50.4 47.5 46.5 46.1 0.8
Revolver Commitment Fee 0.8 1.5 1.5 1.5 — — —
$80.8 $167.8 $145.3 $158.8 $719.7 $54.6 $793.4

Other Future Capital Investments

At June 30, 2023, there have been no material changes to our estimate for restructuring and integration expenses along with spending to support quality systems and quality compliance objectives, as previously disclosed in our 2022 Annual Report on Form 10-K.

Indemnifications

In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. Although we can provide no assurances, we have never incurred, nor do we expect to incur, any liability for indemnification.

Historical Cash Flows

Cash Flows from Operating Activities

Our net cash provided by operations for the six months ended June 30, 2023 was $39.8 million. Net income plus adjustments for non-cash net expenses contributed $151.7 million. Net cash used in operations as a result of changes in operating assets and liabilities was $111.9 million. The changes in operating assets and liabilities included a $76.0 million increase in inventories, a $12.7 million increase in other assets, a $46.9 million decrease in accounts payable, $26.0 million in net changes in income taxes, including excess tax benefits and deferred income taxes and a $0.1 million decrease in accrued liabilities. Offsetting these amounts was a $46.8 million decrease in accounts receivable and a $3.0 million decrease in prepaid expenses and other current assets. The increase in inventory was primarily to build inventory safety stock levels. The increase in other assets was due to the purchase of spare parts. The decrease in accounts payable was due to the timing of payments. The net changes in income taxes was a result of recording the current deferred provision and the timing of payments. The increase in accrued liabilities was primarily due to employee costs. The decrease in accounts receivable was primarily due to the sale of accounts receivable as part of our accounts receivable purchase program with Bank of the West (see Note 21: Accounts Receivable Purchase Program). The decrease in prepaid expenses and other current assets was primarily due to insurance and property taxes.

Our net cash used in operations for the six months ended June 30, 2022 was $62.7 million. Net income plus adjustments for non-cash net expenses contributed $108.2 million. Net cash used in operations as a result of changes in operating assets and liabilities was $170.9 million. The changes in operating assets and liabilities included a $100.0 million increase in inventories, a $17.3 million increase in other assets, a $33.5 million decrease in accrued liabilities and $45.8 million in net changes in income taxes, including excess tax benefits and deferred income taxes and a $1.1 million increase in accounts receivable. Offsetting these amounts was a $4.7 million decrease in prepaid expenses and other current assets and a $22.1 million increase in accounts payable. The increase in inventory was primarily due to the increase in safety stock. The increase in other assets was due to the purchase of spare parts and the capitalization of debt issuance costs allocated to the revolving credit facility. The decrease in accrued liabilities was primarily due to the payout of annual bonuses. The net changes in income taxes was a result of recording the current deferred provision and the timing of payments. The increase in accounts receivable was primarily due to collection efforts and the timing of revenue. The net decrease in prepaid expenses and other current assets was primarily due to a decrease in deferred costs mostly offset by capitalized debt issuance costs allocated to the revolving credit facility. The increase in accounts payable was due to the timing of payments.

Cash Flows from Investing Activities

The following table summarizes the changes in our investing cash flows (in thousands):

Investing Cash Flows: Six months ended June 30, 2023 2022 Change
Purchases of property, plant and equipment $(32,489) $(48,039) $15,550 (1)
Proceeds from sale of assets 1,431 900 531
Business acquisitions, net of cash acquired — (1,844,164) 1,844,164 (2)
Intangible asset additions (4,651) (4,440) (211)
Purchases of investment securities — (3,397) 3,397 (3)
Proceeds from sale of investment securities 2,920 26,198 (23,278) (4)
Net cash used in investing activities $(32,789) $(1,872,942) $1,840,153

(1) Our purchases of property, plant and equipment will also vary from period to period based on additional investments needed to support new and existing products and expansion of our manufacturing facilities.

(2) Our business acquisitions will vary from period to period based upon our current growth strategy and our ability to execute on desirable target companies. On January 6, 2022, we completed the acquisition of Smiths Medical. The cash consideration for the transaction was $1.9 billion, which was financed with existing cash balances and borrowings under the Credit Agreement. Acquired cash was $78.8 million.

(3) Our purchases of investment securities will vary from period to period based on current cash needs, planning for known future transactions and changes in our investment strategy.

(4) Proceeds from the sale of our investment securities will vary from period to period based on the maturity dates of the investments.

Cash Flows from Financing Activities

The following table summarizes the changes in our financing cash flows (in thousands):

Financing Cash Flows: Six months ended June 30, 2023 2022 Change
Proceeds from issuance of long-term debt, net of lender debt issuance costs $— $1,672,631 $(1,672,631) (1)
Principal payments on long-term debt (14,813) (18,125) 3,312 (2)
Payment of third-party debt issuance costs — (1,852) 1,852 (3)
Proceeds from exercise of stock options 2,233 2,992 (759) (4)
Payments on finance leases (436) (321) (115)
Tax withholding payments related to net share settlement of equity awards (8,718) (10,438) 1,720 (5)
Net cash (used in) provided by financing activities $(21,734) $1,644,887 $(1,666,621)

(1) In January 2022, we borrowed an aggregate of $1.7 billion under the Senior Secured Credit Facilities to partially finance our acquisition of Smiths Medical (see Note 17: Long-Term Debt to our accompanying condensed consolidated financial statements for additional information). The proceeds were net of $27.3 million in payments of lender debt issuance costs.

(2) Relates to scheduled principal payments on the Senior Secured Credit Facilities.

(3) Relates to third-party debt issuance costs in connection with entering into the Senior Secured Credit Facilities.

(4) Proceeds from the exercise of stock options will vary from period to period based on the volume of options exercised and the exercise price of the specific options exercised.

(5) During the six months ended June 30, 2023, our employees surrendered 54,371 shares of our common stock from vested restricted stock unit awards as consideration for approximately $8.7 million in minimum statutory withholding obligations paid on their behalf. During the six months ended June 30, 2022, our employees surrendered 44,759 shares of our common stock from vested restricted stock unit awards as consideration for approximately $10.4 million in minimum statutory withholding obligations paid on their behalf.

Our common stock purchase plan, which authorized the repurchase of up to $100.0 million of our common stock, was approved by our Board of Directors in August 2019. This plan has no expiration date. As of June 30, 2023, all of the $100.0 million available for purchase was remaining under the plan.

Critical Accounting Policies

In our 2022 Annual Report on Form 10-K, we identified the critical accounting policies which affect our more significant estimates and assumptions used in preparing our consolidated financial statements. There have been no material changes to our critical accounting policies from those previously disclosed in our 2022 Annual Report on Form 10-K.

New Accounting Pronouncements

See Note 2: New Accounting Pronouncements in Part I, Item 1. "Financial Statements."

Market risk

As filed, 4,715 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Interest Rate Risk

Credit Facility

In connection with the Smiths Medical acquisition on January 6, 2022 we entered into the Senior Secured Credit Facilities totaling approximately $2.2 billion consisting of a variable-rate term loan A facility of $850.0 million, a variable-rate term loan B facility of $850.0 million and a revolving credit facility of $500.0 million. We are exposed to changes in interest rates on all of these variable-rate debt instruments.

The term loan A facility currently bears interest based on Adjusted Term SOFR plus an initial applicable margin of 1.75% per year. The term loan B facility currently bears interest based on Adjusted Term SOFR subject to a 0.50% floor plus an initial applicable margin of 2.5%. We used a sensitivity analysis to measure our interest rate risk exposure. If the SOFR rate increases or decreases 1% from June 30, 2023, the additional annual interest expense or savings related to the term loans would amount to approximately $16.6 million.

In order to mitigate and offset a portion of this interest rate risk exposure associated with these debt instruments we entered into interest rate swaps to achieve a targeted mix of fixed and variable-rate debt. The term loan A swap has an initial notional amount of $300.0 million, reducing to $150.0 million evenly on a quarterly basis excluding its final maturity on March 30, 2027 and we will pay a fixed rate of 1.32% and will receive the greater of 3-month USD SOFR or (0.15)%. The term loan B swap has an initial notional amount of $750.0 million, reducing to $46.9 million evenly on a quarterly basis excluding its final maturity on March 30, 2026 and we will pay a fixed rate of 1.17% and will receive the greater of 3-month USD SOFR or 0.35%. In June 2023, we entered into an additional swap with a notional amount of $300 million with a maturity date of June 30, 2028 and we will pay a fixed rate of 3.8765% starting on June 30, 2023 and receive 3-month USD SOFR. See Note 8: Derivatives and Hedging Activities to the condensed consolidated financial statements in Part I, Item 1 of this Form 10-Q.

Accounts Receivable Purchase Program

Additionally, our accounts receivable purchase program with Bank of the West bears discount rates tied to SOFR. These variable discount rates would affect the amount of factoring costs we incur, and the amount of cash we receive upon the sales of accounts receivable under this program. A 1% increase in SOFR rates on the accounts receivable sales would not have a material impact on our results of operations.

Foreign Currency Exchange Rate Risk

We transact business globally in multiple currencies, some of which are considered volatile. Our international revenues and expenses and working capital positions denominated in these foreign currencies expose us to the risk of fluctuations in foreign currency exchange rates against the U.S. dollar. As the receiver of foreign currencies we are adversely affected by the strengthening of the U.S. dollar and other currencies relative to the operating unit functional currency. Our hedging policy attempts to manage these risks to an acceptable level. We manage our foreign currency exposures on a consolidated basis to take advantage of net exposures and natural offsets, which are then further reduced by the gains and losses of our hedging instruments. Gains and losses on the hedging instruments offset gains and losses on the hedged forecasted transactions and reduce the earnings volatility related to foreign exchange, however we do not hedge our entire foreign exchange exposure and are still subject to earnings volatility due to foreign currency exchange rate risk.

Our foreign currency exchange forward contracts hedge a portion of our forecasted foreign currency-denominated revenues and expenses (principally Mexican Pesos, Euros, Czech Koruna, Japanese Yen, U.S. Dollar, Chinese Renminbi, Canadian Dollar, Swedish Krona and Australian Dollar) that differ from the functional currency of the operating unit. These derivative contracts are designated and qualify as cash flow hedges (see Note 8: Derivatives and Hedging Activities to the condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q). We performed a sensitivity analysis to estimate changes in the fair value of our foreign exchange derivatives due to potential changes in near-term foreign currency exchange rates. At June 30, 2023, the effect of a hypothetical 10% weakening in the actual foreign currency exchange rates used for the applicable currencies would result in an estimated decrease in the fair value of these outstanding derivative contracts by approximately $2.2 million.

Controls and procedures

As filed, 1,575 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls

and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the

desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there

are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible

controls and procedures relative to their costs

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Quarterly Report. Based on the evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 486 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In evaluating an investment in our common stock, investors should consider carefully, among other things, the risk factors previously disclosed in Part I, Item 1A of our 2022 Annual Report on Form 10-K, as well as the information contained in this Quarterly Report, in each case as updated by our periodic reports and registration statements filed with the SEC. There have been no material changes to the risk factors disclosed in Part I. Item 1A of our 2022 Annual Report on Form 10-K.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-04-01 to 2023-06-30$549.3mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2023-01-01 to 2023-06-30$1.12bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-04-01 to 2023-06-30$357.0mus-gaap:CostOfRevenue
Cost of revenue6 months2023-01-01 to 2023-06-30$733.6mus-gaap:CostOfRevenue
Gross profit3 months2023-04-01 to 2023-06-30$192.3mus-gaap:GrossProfit
Gross profit6 months2023-01-01 to 2023-06-30$384.4mus-gaap:GrossProfit
Research and development3 months2023-04-01 to 2023-06-30$22.3mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2023-01-01 to 2023-06-30$42.1mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2023-04-01 to 2023-06-30$150.9mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2023-01-01 to 2023-06-30$303.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-04-01 to 2023-06-30$2.8mus-gaap:OperatingIncomeLoss
Operating income6 months2023-01-01 to 2023-06-30$12.2mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-04-01 to 2023-06-30$24.1mus-gaap:InterestExpense
Interest expense6 months2023-01-01 to 2023-06-30$46.6mus-gaap:InterestExpense
Income tax3 months2023-04-01 to 2023-06-30−$12.9mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2023-01-01 to 2023-06-30−$16.5mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-04-01 to 2023-06-30−$9.9mus-gaap:NetIncomeLoss
Net income6 months2023-01-01 to 2023-06-30−$19.7mus-gaap:ProfitLoss
Diluted EPS3 months2023-04-01 to 2023-06-30−$0.41us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2023-01-01 to 2023-06-30−$0.82us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-04-01 to 2023-06-30−$0.41us-gaap:EarningsPerShareBasic
Basic EPS6 months2023-01-01 to 2023-06-30−$0.82us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-04-01 to 2023-06-3024,075,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2023-01-01 to 2023-06-3024,045,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2023-01-01 to 2023-06-30$39.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2023-01-01 to 2023-06-30$32.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Current assetsAt period end2023-06-30$1.24bnus-gaap:AssetsCurrent
Total assetsAt period end2023-06-30$4.46bnus-gaap:Assets
Current liabilitiesAt period end2023-06-30$483.9mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2023-06-30$1.60bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2023-06-30$40.4mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2023-06-30$2.11bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000883984-23-000030. Last ingested by Listed: Nov 14, 2026, 20:54 ET. Listed shows no prices and gives no investment advice.